Akorn, Inc.

Akorn, Inc. Signs Exclusive Development and Supply Agreement with Haemonetics Corporation for Three Premix Products

Published in Hospital Business Week, August 5th, 2007

Akorn, Inc. (NASDAQ: AKRX) announced that it has signed an exclusive development and supply agreement with Haemonetics Corporation (NYSE: HAE) for three premix products. Premix medications are ready to use intravenous drug products which eliminate compounding steps in the pharmacy or at the point of care.

Under the terms of the agreement, Akorn will be responsible for development, marketing and distribution. Haemonetics will manufacture the three products at its intravenous solutions manufacturing facility in Union, SC. The products are all expected to launch between 2010 and 2011, and represent a current total U.S. market size of approximately $500 million. One of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hospital Business Week

Source: Hospital Business Week (2007-08-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry